Patents by Inventor Thierry Chardes
Thierry Chardes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230040928Abstract: The present invention relates to antibodies having specificity to HER4 and uses thereof, which are able to induce biased 4ICD routing/signaling. The inventors have isolated by antibody phage display three fully human anti-HER4 single-chain variable antibody fragment (scFv), selected on human HER4 extracellular domain, referred as C6 mAb, D5 mAb and F4 mAb and one fully human anti-HER4 scFv named H2 mAb, selected on NRG 1?1-stimulated EGFR/HER4 JMaCYT1-transfected NIH3T3 cells. In particular, the present invention relates to an isolated anti-HER4 antibody, wherein said antibody binds to an epitope of the HER4 protein.Type: ApplicationFiled: December 8, 2020Publication date: February 9, 2023Inventors: Andre PELEGRIN, Pierre MARTINEAU, Thierry CHARDES, Romain LANOTTE
-
Publication number: 20220290151Abstract: In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients' tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that MIS siRNA inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.Type: ApplicationFiled: September 25, 2020Publication date: September 15, 2022Inventors: Andre PELEGRIN, Thierry CHARDES, Isabelle NAVARRO-TEULON, Maeva CHAUVIN
-
Patent number: 11001634Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.Type: GrantFiled: May 2, 2016Date of Patent: May 11, 2021Assignees: GAMAMABS PHARMA, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIERInventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
-
Patent number: 10526415Abstract: The invention relates to human anti-Cath-D neutralizing monoclonal antibodies and uses thereof. More particularly, the invention relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.Type: GrantFiled: May 20, 2016Date of Patent: January 7, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIERInventors: Emmanuelle Liaudet-Coopman, Thierry Chardes, Pierre Martineau, Yahya Ashraf
-
Patent number: 10196455Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.Type: GrantFiled: November 7, 2013Date of Patent: February 5, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier, Institut Regional du Cancer de MontpellierInventors: Thierry Chardes, Nadege Gaborit, Christel Larbouret, Andre Pelegrin
-
Publication number: 20180291098Abstract: The disclosure relates to human anti-NRG1 neutralizing monoclonal antibodies that do not interfere with the NRG1 binding to the HER3 receptor and uses thereof. More particularly, an isolated human monoclonal antibody comprising a heavy and light chain variable regions with specific CDRs defined by their sequences is disclosed.Type: ApplicationFiled: October 26, 2016Publication date: October 11, 2018Inventors: Charline Ogier, Christel Larbouret, Andre Pelegrin, Thierry Chardes
-
Publication number: 20180155433Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.Type: ApplicationFiled: May 2, 2016Publication date: June 7, 2018Inventors: Thierry CHARDÈS, Olivier DUBREUIL, André PELEGRIN, Christel LARBOURET, Jean-François PROST, Jean-Marc BARRET, Stéphane DEGOVE
-
Publication number: 20180127510Abstract: The invention relates to human anti-Cath-D neutralizing monoclonal antibodies and uses thereof. More particularly, the invention relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.Type: ApplicationFiled: May 20, 2016Publication date: May 10, 2018Inventors: Emmanuelle LIAUDET-COOPMAN, Thierry CHARDES, Pierre MARTINEAU, Yahya ASHRAF
-
Publication number: 20160319033Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.Type: ApplicationFiled: November 7, 2013Publication date: November 3, 2016Inventors: Thierry Chardes, Nadege Gaborit, Christel Larbouret, Andre Pelegrin
-
Patent number: 9409988Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.Type: GrantFiled: June 22, 2012Date of Patent: August 9, 2016Assignees: INSERM (Institut National De La Sante Et De La Recherche Medicale), ORIBASE Pharma, UNIVERSITE De Montpellier 1, INSTITUT Regional Du Cancer De Montpellier-Val D'AurelleInventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Patent number: 9346883Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.Type: GrantFiled: May 11, 2012Date of Patent: May 24, 2016Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Gamamabs Pharma SAInventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
-
Patent number: 9249228Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.Type: GrantFiled: June 22, 2012Date of Patent: February 2, 2016Assignees: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Patent number: 9127065Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.Type: GrantFiled: May 21, 2012Date of Patent: September 8, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Val d'Aurelle—Paul Lamarque, Universite de Montpellier 1Inventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
-
Publication number: 20140302041Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.Type: ApplicationFiled: June 22, 2012Publication date: October 9, 2014Applicants: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Publication number: 20140227283Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.Type: ApplicationFiled: June 22, 2012Publication date: August 14, 2014Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Regional du Cancer de Montpellier-Val d'Aurelle, UNIVERSITE DE MONTPELLIER 1, OriBase PharmaInventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Publication number: 20140141019Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.Type: ApplicationFiled: May 11, 2012Publication date: May 22, 2014Applicant: INSERM (INSTITUT NATIONALDE LA SENTE ET DE LA RECHERCHE MEDICALE)Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
-
Publication number: 20140112931Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.Type: ApplicationFiled: May 21, 2012Publication date: April 24, 2014Applicants: UNIVERSITE DE MONTPELLIER 1, CENTRE VAL D'AURELLE - PAUL LAMARQUEInventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
-
Patent number: 7482000Abstract: A mutant Fab fragment of the 13B8.2 anti-CD4 antibody that binds a CD4 molecule and includes a mutation of at least one residue in a position situated in the VH variable domain of the heavy chain and/or in a position situated in the V? variable domain of the light chain.Type: GrantFiled: January 5, 2005Date of Patent: January 27, 2009Assignee: Centre National de la Recherche Scientifique - CNRSInventors: Christian Devaux, Cédric Bes, Laurence Briant-Longuet, Martine Cerutti, Gérard Devauchelle, Thierry Chardes, Claude Granier, Bernard Pau
-
Publication number: 20050226874Abstract: A mutant Fab fragment of the 13B8.2 anti-CD4 antibody that binds a CD4 molecule and includes a mutation of at least one residue in a position situated in the VH variable domain of the heavy chain and/or in a position situated in the V? variable domain of the light chain.Type: ApplicationFiled: January 5, 2005Publication date: October 13, 2005Applicant: Centre National de la Recherche Scientifique - CNRS, a corporation of FranceInventors: Christian Devaux, Cedric Bes, Laurence Briant-Longuet, Martine Cerutti, Gerard Devauchelle, Thierry Chardes, Claude Granier, Bernard Pau
-
Publication number: 20030113322Abstract: An isolated CDR-derived polypeptide from monoclonal antibody 13B8.2, a pharmaceutical composition including a pharmaceutically acceptable carrier and at least a peptide, and a method for treating a subject suffering from an autoimmune disorder, including administering to the subject a therapeutically effective amount of a pharmaceutical composition, a method for treating a subject suffering from a transplant rejection including administering to the subject a therapeutically effective amount of a pharmaceutical composition, a method for treating a subject suffering from an HIV immunodeficiency disorder including administering to the subject a therapeutically effective amount of a pharmaceutical composition and a method for treating a subject suffering from a tumoral disorder including administering to the subject a therapeutically effective amount of a pharmaceutical composition.Type: ApplicationFiled: December 18, 2002Publication date: June 19, 2003Inventors: Cedric Bes, Laurence Briant-Longuet, Martine Cerutti, Thierry Chardes, Gerard DeVauchelle, Christian DeVaux, Claude Granier, Claude Mawas, Daniel Olive, Bernard Pau